1. Dispenzieri A, Zhang L, Fonesca R, Vesole DH, Greipp PR . Single agent bortezomib is associated with a high response rate in patients with high risk multiple myeloma. A phase II study from the Eastern Cooperative Oncology Group (E2A02). Blood 2006; 108 (Part 1): 1006a, no. 3527 (abstract).
2. Anderson KC . The role of immunomodulatory drugs in multiple myeloma (review). Semin Hematol 2003; 40: 23–32.
3. Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust S et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. Blood 2006; 108 (Part 1): 239a, no. 798 (abstract).
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.
5. Buckner CD, Fefer A, Bensinger WI, Storb R, Durie BG, Appelbaum FR et al. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle Experience. Eur J Haematol 1989; 43: 186–190.